Samson M K, Baker L H, Benjamin R S, Lane M, Plager C
Cancer Treat Rep. 1979 Nov-Dec;63(11-12):2027-9.
cis-Dichlorodiammineplatinum(II) (DDP), at a dose of 15 mg/m2/day x 5 consecutive days, was administered to 68 evaluable patients with metastatic soft tissue and bony sarcomas. All patients, except one, had received extensive prior chemotherapy and had had progressive disease at the start of the study. Responses observed included one complete response in a patient with mesothelioma and three partial responses in patients with soft tissue sarcomas (7%). No responses were seen in 18 patients with bony sarcomas. Significant leukopenia and thrombocytopenia were observed in less than 20% of evaluable courses, although two patients manifested life-threatening leukopenia (less than 1000 cells/microliter) and three had life-threatening thrombocytopenia (less than 24,000 cells/microliter). Nephrotoxicity was noted in less than 25% of evaluable courses. Nausea and/or vomiting was recorded in 55% of evaluable courses. DDP is considered to be marginally active in the secondary treatment of metastatic sarcomas at this dose and schedule. Further studies of DDP in mesothelioma are indicated.
顺二氯二氨铂（II）（DDP），剂量为15毫克/平方米/天，连续5天给药，用于68例可评估的转移性软组织和骨肉瘤患者。除1例患者外，所有患者在研究开始前均接受过广泛的化疗且病情进展。观察到的反应包括1例间皮瘤患者完全缓解，3例软组织肉瘤患者部分缓解（7%）。18例骨肉瘤患者未观察到缓解。在不到20%的可评估疗程中观察到显著的白细胞减少和血小板减少，尽管有2例患者出现危及生命的白细胞减少（低于1000个细胞/微升），3例患者出现危及生命的血小板减少（低于24,000个细胞/微升）。在不到25%的可评估疗程中发现肾毒性。55%的可评估疗程记录有恶心和/或呕吐。在此剂量和给药方案下，DDP被认为在转移性肉瘤的二线治疗中活性有限。有必要对DDP在间皮瘤中的进一步研究。
